pharmaphorum
OCTOBER 6, 2022
An artificial intelligence-powered digital health worker has been unveiled by the World Health Organisation (WHO) as its latest tool for disseminating reliable health information to the public. Originally developed by New Zealand tech company Soul Machines with support of the Qatar Ministry of Health, the first version of the virtual health worker was used to combat misinformation about the pandemic.
Pharmaceutical Technology
OCTOBER 6, 2022
Pfizer has acquired all the outstanding shares of the common stock of biopharmaceutical firm Global Blood Therapeutics (GBT) in a deal worth nearly $5.4bn. The total enterprise value comprised debt and the net of cash acquired. With the latest acquisition, GBT became a wholly-owned Pfizer subsidiary. GBT discovers and develops life-changing therapies for ailments with an initial focus on sickle cell disease (SCD).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MedCity News
OCTOBER 6, 2022
TALON was recently crowned winner of the Pitch Perfect contest at MedCity’s Invest Digital Health conference in Dallas. The company offers a suite of solutions to help stay compliant with the Transparency in Coverage Rule.
pharmaphorum
OCTOBER 6, 2022
Biological systems are hugely complex, with a staggering number of pathways interacting every millisecond. The downstream effects of just one biological change are enormous. So, when a new disease emerges, researchers have a near-impossible task working upstream from symptoms to identify the underlying cause and biological mechanisms causing disease.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
MedCity News
OCTOBER 6, 2022
A neighborhood pharmacy owner was the largest purchaser of oxycodone among retail pharmacies in the entire state of Pennsylvania by 2016 and pled guilty to charges of conspiracy and fraud.
pharmaphorum
OCTOBER 6, 2022
In this instalment of Health Innovators, Paul Tunnah, Healthware’s chief content officer, sits down with Dr Anthony Yanni, senior vice president and global head of patient centricity at Astellas Pharma. “Patient centricity” is a central value as pharma companies look to innovate their products and processes, but is it also in danger of losing its meaning and becoming just another pharma business buzzword?
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
Copyright Clearance Center
OCTOBER 6, 2022
The post CCC Honored as Gold Winner in Customer Service Department of the Year Category From the Best in Biz Awards 2022 International appeared first on Copyright Clearance Center.
MedCity News
OCTOBER 6, 2022
Digital health could range from EMR to Remote Patient Monitoring (RPM) solutions. For the purposes of this article, we’re focusing on patient interfacing solutions. Use these 15 screening questions to help your organization determine whether a solution is right for you.
pharmaphorum
OCTOBER 6, 2022
Servier is already in the process of transforming itself into a much bigger player in cancer, and has just tripled its sales objectives for the category. Fresh with a new brand identity, the France-headquartered pharma group has pledged to grow its oncology sales from its current objective of €1 billion in 2025 to €3 billion in 2030, continuing a diversification of its business from its traditional focus on cardiovascular diseases.
MedCity News
OCTOBER 6, 2022
Nested Therapeutics uses computational techniques to map mutations and protein structures, identifying previously unseen places where a cancer drug can bind. The Versant Ventures-founded startup is now out of stealth with two programs on the path to the clinic.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
European Pharmaceutical Review
OCTOBER 6, 2022
Microbial identification is a globally expanding market, predicted by new research to hold a value of $3.7 billion by the end of 2022 and $10.7 billion in 2032, propelled by a compound annual growth rate (CAGR) of 11.3 percent, led primarily by the rapid advancement of technology, In 2021, the market share for bacterial identification systems was 28.4 percent.
MedCity News
OCTOBER 6, 2022
Medical imaging company Genetesis recently closed a $17.5 million Series C funding round, bringing its total funding to date to more than $40 million. Most of the funds will go toward clinical trials for the company’s 5-minute test to detect ischemic heart disease, which uses magnetocardiography. Genetesis anticipates the test entering the market in early 2023.
PharmaTimes
OCTOBER 6, 2022
The Airport Region in Central Germany’ presents itself as an attractive location for the international pharmaceutical industry
MedCity News
OCTOBER 6, 2022
Northwell recently invested $3 million in Hume AI, an expressive communication research lab and AI startup. The health system is partnering with Hume to develop machine learning models designed to better understand patients’ vocal and nonverbal communications.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
European Pharmaceutical Review
OCTOBER 6, 2022
The US Food and Drug Administration (FDA) has approved Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody (PATHWAY anti-HER2 (4B5) test), which identifies low HER2 expression in metastatic breast cancer. The approval redefines the pool of patients to be optioned for Enhertu (fam-trastuzumab deruxtecan-nxki), a modified HER2-directed antibody drug conjugate (ADC).
MedCity News
OCTOBER 6, 2022
Enrollees in high-deductible health plans are 6.6% less likely to receive substance use disorder treatment than those without a high-deductible health plan. Having a high-deductible health plan led to 21% less health plan spending, but an increase of 14% in out-of-pocket spending. This can deter some receiving care, the researchers argued.
PharmaTimes
OCTOBER 6, 2022
Partnership will maximise the chance of successfully progressing its research projects
MedCity News
OCTOBER 6, 2022
Red Tree Venture Capital has closed a $272 million fund focused on investing in West Coast life sciences companies. The firm’s founders say they’re filling a need by providing financial support for innovations emerging from the region’s academic labs.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
PharmaTimes
OCTOBER 6, 2022
Link up will boost independent community pharmacies’ online presence to broaden services
MedCity News
OCTOBER 6, 2022
HLTH 2022 will include compelling discussions across eight stages from the state of women’s health, sleep tech, healthcare CEOs’ perspectives on collaboration partners, the mind-body connection in health, investment trends, and more. Register today!
Pharmaceutical Technology
OCTOBER 6, 2022
BioLink Life Sciences has received a contract worth $750,000 from the US Biomedical Advanced Research and Development Authority (BARDA) to develop Ramatroban for treating Covid-19 pneumonia patients in the hospital setting. A dual blocker of thromboxane and prostanoid receptors, Ramatroban showed efficacy in animal models of atherosclerosis, respiratory dysfunction, thrombosis and sepsis.
MedCity News
OCTOBER 6, 2022
In migrating from HL7 v2 (or a proprietary format) to FHIR, your IT or engineering group will be teaching a dozen different systems to speak a new, highly technical language.
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
pharmaphorum
OCTOBER 6, 2022
NHS England has launched a programme to investigate how data sharing and digital health technologies (DHT) could close an “historic treatment gap in mental health provision.” It has launched a tender process to find suppliers – both large and small – which can contribute to “multiple investigatory pieces of work” that will run over a four-month period, so as to gauge how data-sharing and DHTs could be folded into the care of people with mental health needs.
Pharmaceutical Technology
OCTOBER 6, 2022
Intravacc has received a contract worth $14.6m from the US National Institutes of Health (NIH) unit National Institute of Allergy and Infectious Diseases (NIAID) to develop a prophylactic intranasal vaccine against Neisseria gonorrhoeae (NG). Leveraging its outer membrane vesicles (OMV) platform technology, Intravacc will develop the vaccine. Named NGoXIM, the NG vaccine is based on gonococcal OMVs merged with sustained-release microspheres comprising recombinant human IL-12.
Pharma Pathway
OCTOBER 6, 2022
Steril-Gene Life Sciences-Openings for Freshers & Experienced in QC/ QA/ QC-Micro/ Production/ Technology Transfer-Apply Now. Job Description. Steril-Gene Life Sciences, Pondicherry (A Group Unit of the Madras Pharmaceuticals) one of the most reputed FDA approved Pharmaceutical manufacturing Company looking suitable Candidates for the below positions.
Eversana Intouch
OCTOBER 6, 2022
Recently, Taegan Grice, Managing Director, Creative, EVERSANA INTOUCH Engage, was interviewed by Endpoints News for a feature story on whether scientific imagery is still effective in pharmaceutical advertising. There can be pros and cons, the article argued, since we live in complicated times regarding public opinion about science, thanks to misinformation.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
PharmaTech
OCTOBER 6, 2022
The Nexera Prep preparative and purification LC improves productivity via efficient preparative work using application-specific LC (-MS) solutions. It provides better prep processes for discovery and purification of functional components.
pharmaphorum
OCTOBER 6, 2022
Any new drug launch must overcome numerous obstacles in the pursuit of success. Many of these challenges are exacerbated in oncology, where the treatment landscape rapidly evolves with novel mechanisms of actions (e.g., cell therapy, bi/tri-specific antibodies), where there are ever-changing regulatory requirements, the use of biomarkers, etc. Today’s oncology launch landscape is highly saturated and competitive, cumulatively presenting significant challenges, particularly for small and emerging
Pharmaceutical Technology
OCTOBER 6, 2022
According to Adam Bradbury, GlobalData PharmSource analyst “[…] evidence indicates that containment facilities are in high demand and will be increasingly so in future as the oncology pipeline and the use of cytotoxic drugs continues to grow.” But despite this surge in demand, research from GlobalData shows that many CMOs have decreased in-house, non-containment, small molecule manufacturing.
pharmaphorum
OCTOBER 6, 2022
A bipartisan bill has been introduced in the US Congress that will try to block Centers for Medicare and Medicaid Services (CMS) restrictions on Biogen’s Alzheimer’s therapy Aduhelm being extended to newer drugs for the disease. The Mandating Exclusive Review of Individual Treatments (MERIT) Act – co-sponsored by Representatives Nanette Barragán (D-CA) and Vern Buchanan (R-FL) – has been tabled shortly after Eisai and Biogen reported positive top-line data for their Aduhelm follow-up
Advertisement
The global landscape of clinical trials is rapidly changing as studies become more complex. An increasing number of sponsors are seeking enhanced flexibility in their supply chains to address a variety of clinical supply challenges, including patient demand and reducing delays. Demand-led supply and direct-to-patient distribution are next-generation solutions that are helping to meet these growing needs, allowing for more streamlined processes and patient-centric studies.
Expert insights. Personalized for you.
143 
Let's personalize your content